• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Intarcia Therapeutics

edit

Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company’s products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.

Recent Milestones

edit

• 
  Intarcia Therapeutics received $210M in Series C funding. (11/16/12)
  Posted 11/16/12 at 6:22pm via dowjones.com
• 
  Intarcia Therapeutics — Intarcia Therapeutics Names Kurt Graves To New Executive Chairman Post. (9/17/10)
  Posted 10/13/10 at 11:35pm via dowjones.com
• 
  Intarcia Therapeutics received $5M in Series B funding. (9/8/10)
  Posted 9/8/10 at 6:12pm via venturebeat.com
• 
  Intarcia Therapeutics received in Series A funding. (3/20/07)
  Posted 10/9/09 at 2:07am via venturebeat.com
• 
  Intarcia Therapeutics added Karling Alice Leung as CEO.
  Posted 10/9/09 at 2:07am
• 
  Intarcia Therapeutics added James M. Ahlers as CFO.
  Posted 10/9/09 at 2:07am
• 
  Intarcia Therapeutics added Kurt Graves as Chairman, President and CEO.
  Posted 4/2/12 at 6:04pm

Videos

Screenshots

edit

Sources

1. Intarcia restarts with $50M for hepatitis, diabetes treatments (deals.venturebeat.com) [edit]
2. Intarcia Therapeutics raises $5M to treat long-term conditions (deals.venturebeat.com) [edit]
3. Intarcia Amasses $210M in Equity, Debt Financing for Type 2 Diabetes Therapy (pevc.dowjones.com) [edit]
Intarcia Therapeutics Names Kurt Graves To New Executive Chairman Post (fis.dowjones.com) [edit]